Skip to main content

Altimmune, Inc.

corporate_fare Company Profile

Altimmune, Inc.

ALT·NASDAQ·Life Sciences·CIK 0001326190

Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing new treatments for serious liver diseases. The company's main product candidate is pemvidutide (formerly ALT-801), a balanced 1:1 glucagon/GLP-1 dual receptor agonist. Pemvidutide is being developed to treat metabolic dysfunction-associated steatohepatitis ("MASH"), alcohol use disorder ("AUD"), and alcohol-associated liver disease ("ALD"). Altimmune may also explore other uses for pemvidutide based on its clinical profile. Altimmune acquired pemvidutide through the acquisition of Spitfire Pharma Inc. in July 2019. Pemvidutide was designed as a MASH therapeutic to target both metabolic and liver-specific effects. Preclinical studies in a mouse model of MASH showed efficacy. In initial human trials, pemvidutide demonstrated weight loss and liver effects. Subsequent evaluation in participants with fatty liver disease, or metabolic-dysfunction associated liver disease (MASLD), showed significant reductions in liver fat content and weight loss. These findings led to the biopsy-driven IMPACT Phase 2b trial for MASH. The MOMENTUM Phase 2 trial in overweight and obese participants further characterized pemvidutide's effects, showing significant weight loss with relative preservation of lean muscle mass and improvements in serum lipids linked to cardiovascular disease. Beyond the recently completed IMPACT trial, pemvidutide is currently being studied in participants with AUD and ALD, with evidence suggesting it may reduce alcohol cravings and potentially reverse alcohol's harmful effects on the liver. Pemvidutide is a novel, investigational peptide.

Altimmune, Inc. (NASDAQ:ALT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for ALT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for ALT spans 10-Q, 8-K, 424B5, S-3MEF.

Recent high-impact activity:

  • Altimmune Q3 Loss Widens to $31.6M as MASH Phase 3 Spending Ramps; $494.9M Liquidity
  • Altimmune Q3 Loss Widens to $31.6M, Missing Estimates as Trial Costs Climb
  • Pemvidutide Cuts Heavy Drinking Days in Phase 2 AUD Trial; FDA Meeting Set for December
  • Altimmune Q2 2026: $519M Cash, Phase 3 PERFORMA Launch, and $45.4M Net Loss
  • Altimmune Q2 Loss Beats Estimates; FDA Meeting Planned for AUD Program

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$41K
Net Income
-$88.09M
Diluted EPS
-$1.00
Op. Cash Flow
-$67.53M
Operating Income
-$94.49M
Cash & Equivalents
$43.76M
Total Debt
$34.29M
Debt / Equity
0.15×
Net Margin
-2148.61×
Shares Outstanding
110.88M sh
Source: 10-K · filed 2026-03-06 · accession 0001326190-26-000018

Short Interest & Short Volume

12.16 days to cover

FINRA reported short interest of 42,131,170 shares in ALT as of the October 30, 2026 settlement, a 0.2% decrease from the prior period — about 12.2 days to cover at its recent average daily volume. On November 20, 2026, 54.2% of ALT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)42,131,170 shares as of October 30, 2026
Change vs prior period▼ 0.2%
Days to cover12.16 at avg daily volume of 3,464,215
Daily short volume (FINRA facilities)54.2% of 2,219,906 shares on November 20, 2026
5-day average short volume57.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$1.35 +1.83% today
52-week range · as of 2026-11-12 $1.35 – $6.44
Market cap
$258.8M
Volume
4.1M (1.0× avg)
3-mo avg 4M
Live data · 2026-11-21 03:37 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed ALT - Latest Insights

ALT
Nov 12, 2026, 4:33 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.65
Real-time Price: $1.35 info
Change: -$0.2951 (-18%) info
Market Cap: $258.804M info
ALT
Nov 12, 2026, 7:38 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.92
Real-time Price: $1.35 info
Change: -$0.5607 (-29%) info
Market Cap: $258.804M info
ALT
Nov 09, 2026, 12:30 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.14
Real-time Price: $1.35 info
Change: -$0.7807 (-37%) info
Market Cap: $258.804M info
ALT
Aug 12, 2026, 4:04 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.96
Real-time Price: $1.35 info
Change: -$1.61 (-54%) info
Market Cap: $258.804M info
ALT
Aug 12, 2026, 7:43 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $3.06
Real-time Price: $1.35 info
Change: -$1.71 (-56%) info
Market Cap: $258.804M info
ALT
Aug 12, 2026, 7:33 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.01
Real-time Price: $1.35 info
Change: -$1.66 (-55%) info
Market Cap: $258.804M info
ALT
Jul 28, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.44
Real-time Price: $1.35 info
Change: -$2.09 (-61%) info
Market Cap: $258.804M info
ALT
May 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $2.96
Real-time Price: $1.35 info
Change: -$1.61 (-54%) info
Market Cap: $258.804M info
ALT
May 13, 2026, 4:21 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.99
Real-time Price: $1.35 info
Change: -$1.64 (-55%) info
Market Cap: $258.804M info
ALT
May 13, 2026, 4:13 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.99
Real-time Price: $1.35 info
Change: -$1.64 (-55%) info
Market Cap: $258.804M info
ALT
May 13, 2026, 4:04 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.02
Real-time Price: $1.35 info
Change: -$1.67 (-55%) info
Market Cap: $258.804M info
ALT
May 13, 2026, 7:34 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.11
Real-time Price: $1.35 info
Change: -$1.75 (-56%) info
Market Cap: $258.804M info
ALT
Apr 23, 2026, 9:29 PM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $2.95
Real-time Price: $1.35 info
Change: -$1.60 (-54%) info
Market Cap: $258.804M info
ALT
Apr 22, 2026, 11:28 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $3.05
Real-time Price: $1.35 info
Change: -$1.70 (-56%) info
Market Cap: $258.804M info
ALT
Apr 22, 2026, 9:15 PM EDT
Filing Type: S-3MEF
Importance Score:
8
Price at Filing: $3.05
Real-time Price: $1.35 info
Change: -$1.70 (-56%) info
Market Cap: $258.804M info
ALT
Apr 22, 2026, 5:24 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $3.03
Real-time Price: $1.35 info
Change: -$1.68 (-55%) info
Market Cap: $258.804M info
ALT
Apr 22, 2026, 4:19 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.92
Real-time Price: $1.35 info
Change: -$1.57 (-54%) info
Market Cap: $258.804M info
ALT
Apr 16, 2026, 5:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.51
Real-time Price: $1.35 info
Change: -$2.16 (-61%) info
Market Cap: $258.804M info
ALT
Mar 17, 2026, 7:05 AM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $3.61
Real-time Price: $1.35 info
Change: -$2.26 (-62%) info
Market Cap: $258.804M info
ALT
Mar 06, 2026, 8:01 AM EST
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $3.61
Real-time Price: $1.35 info
Change: -$2.26 (-62%) info
Market Cap: $258.804M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets